In the Spotlight...
A dendritic cell-like transition of T cells is associated with spontaneous remission of adult T-cell leukemia-lymphoma
CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target
CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation
CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression
Previous Digests
EPO acts as a tumor’s doping agent to evade immunosurveillance
May 7, 2025
While some biomarkers, such as low tumor mutational burden, have been associated with immune-cold tumors that respond poorly to immune checkpoint blockade (ICB), the mechanisms underlying the immunosuppressive tumor microenvironment (TME) remain largely unknown. Assessing this question, Chiu et...
Treg depletion in brain tumors enhances antitumor responses
April 30, 2025
Glioblastoma and metastases in the brain are difficult to treat with immunotherapy, in part due to poor immune infiltration and a suppressive immune microenvironment, which can be marked by Tregs. Investigating ways of targeting Tregs, Galvez-Cancino et al. investigated...
Prime time: secondary prolonged DC priming boosts high-affinity T cell responses
April 23, 2025
After initial priming through interaction with dendritic cells (DCs), CD8+ T cells disengage and migrate, but little is known about how cytokine signals are transmitted or received by these cells for differentiation during this migration. Jobin, Seetharama, et al...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
